Effects of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, on metabolic profile in patients with type 2 diabetes

被引：0
|
作者：
Pirro, V. [1 ]
Willency, J. A. [1 ]
Wilson, J. M. [1 ]
Roth, K. D. [1 ]
Lin, Y. [1 ]
Collins, K. A. L. [1 ]
Ruotolo, G. [1 ]
Haupt, A. [1 ]
Newgard, C. B. [2 ]
Duffin, K. L. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Duke Mol Physiol Inst, Durham, NC USA
来源：
DIABETOLOGIA | 2020年 / 63卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
146
引用
收藏
页码：S73 / S73
页数：1
相关论文
共 50 条
  • [1] Effects of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, on lipid profiling in patients with type 2 diabetes
    Ruotolo, G.
    Roth, K. D.
    Milligan, P. L.
    Lin, Y.
    Wilson, J. M.
    Pirro, V
    Duffin, K. L.
    Haupt, A.
    [J]. EUROPEAN HEART JOURNAL, 2020, 41 : 3056 - 3056
  • [2] Tirzepatide: A Novel Dual GIP and GLP-1 Receptor Agonist
    Wong, Elaine
    [J]. JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2023, 19 (01):
  • [3] Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
    Hartman, Mark L.
    Sanyal, Arun J.
    Loomba, Rohit
    Wilson, Jonathan M.
    Nikooienejad, Amir
    Bray, Ross
    Karanikas, Chrisanthi A.
    Duffin, Kevin L.
    Robins, Deborah A.
    Haupt, Axel
    [J]. DIABETES CARE, 2020, 43 (06) : 1352 - 1355
  • [4] The Dual GIP/GLP-1 Receptor Agonist Tirzepatide Improves Cardiovascular Risk Protein Biomarkers in Patients With Type 2 Diabetes
    Wilson, Jonathan M.
    Lin, Yanzhu
    Considine, Gary
    Cox, Amy L.
    Bowsman, Lenden M.
    Robins, Deborah A.
    Riesmeyer, Jeffrey S.
    Haupt, Axel
    Duffin, Kevin
    Ruotolo, Giacomo
    [J]. CIRCULATION, 2020, 142
  • [5] Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes
    Nowak, Mariusz
    Nowak, Wojciech
    Grzeszczak, Wladyslaw
    [J]. ENDOKRYNOLOGIA POLSKA, 2022, 73 (04) : 745 - 755
  • [6] Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
    Willard, Francis S.
    Douros, Jonathan D.
    Gabe, Maria
    Showalter, Aaron D.
    Wainscott, David B.
    Suter, Todd M.
    Capozzi, Megan E.
    van der Velden, Wijnand J. C.
    Stutsman, Cynthia
    Cardona, Guemalli R.
    Urva, Shweta
    Emmerson, Paul J.
    Holst, Jens J.
    D'Alessio, David A.
    Coghlan, Matthew P.
    Rosenkilde, Mette M.
    Campbell, Jonathan E.
    Sloop, Kyle W.
    [J]. JCI INSIGHT, 2020, 5 (17)
  • [7] Effects of tirzepatide (TZP), a novel dual GIP and GLP-1 receptor agonist, on biomarkers of non-alcoholic steatohepatitis (NASH) in patients with type 2 diabetes
    Haupt, A.
    Sanyal, A.
    Loomba, R.
    Wilson, J.
    Bray, R.
    Nikooienejad, A.
    Duffin, K.
    Robins, D.
    Hartman, M.
    [J]. DIABETOLOGIA, 2019, 62 : S91 - S91
  • [8] Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
    Urva, Shweta
    Quinlan, Tonya
    Landry, John
    Martin, Jennifer
    Loghin, Corina
    [J]. CLINICAL PHARMACOKINETICS, 2021, 60 (08) : 1049 - 1059
  • [9] Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
    Urva, Shweta
    Quinlan, Tonya
    Landry, John
    Ma, Xiaosu
    Martin, Jennifer A.
    Benson, Charles T.
    [J]. CLINICAL PHARMACOKINETICS, 2022, 61 (07) : 1057 - 1067
  • [10] Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
    Shweta Urva
    Tonya Quinlan
    John Landry
    Xiaosu Ma
    Jennifer A. Martin
    Charles T. Benson
    [J]. Clinical Pharmacokinetics, 2022, 61 : 1057 - 1067
12345